HeiseT, HermanskiL, NosekL, FeldmanA, RasmussenS, HaarH. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obesity Metab, 2012; 14: 859–64.
3.
HeiseT, NosekL, BöttcherSG, HastrupH, HaahrH. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obesity Metab, 2012; 14: 944–50.
4.
HellerS, BuseJ, FisherM, GargS, MarreM, MerkerL, RenardE, Russel-JonesD, PhilotheouA, Ocampo FranciscoAM, PeiH, BodeB. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, 2012; 379: 1489–97.
5.
RatnerRE, GoughSCL, MathieuC, Del PratoS, BodeB, MersebachH, EndahlL, ZinmanB. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obesity Metab, 2013; 15: 175–84.
6.
NiskanenL, LeiterLA, FranekE, WengJ, DamciT, Muños-TorresM, DonnetJ-P, EndahlL, Vang Skjöth, VaagA. Comparison of a soluble co-formulation of insulin degludec/aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol, 2012; 167: 287–94.
